Opthea Limited (CKDXF)

Opthea Limited (CKDXF) Healthcare & Pipeline Overview

Opthea Limited is an Australian clinical-stage biopharmaceutical company pioneering novel therapies for severe eye diseases, including wet AMD and DME. Leveraging an intellectual property portfolio centered on VEGF-C, VEGF-D, and VEGFR-3, its lead asset, OPT 302, aims to address significant unmet medical needs in ophthalmology.

What Is the Investment Thesis for CKDXF?

Opthea Limited presents an investment thesis centered on its lead clinical asset, OPT 302, and its potential to address significant unmet needs in the large and growing ophthalmology market. The company's strategy focuses on a novel, first-in-class approach by inhibiting VEGF-C and VEGF-D, intended for combination therapy with existing VEGF-A inhibitors for wet AMD and DME. This dual-pathway inhibition could offer superior efficacy for patients who are sub-optimal responders to current monotherapies. With a market capitalization of $13.68M and a reported gross margin of 100.0%, Opthea is currently in the R&D phase, indicating future revenue potential is contingent on successful clinical trial outcomes and regulatory approvals. The intellectual property covering VEGF-C, VEGF-D, and VEGFR-3 provides a competitive moat. Successful progression of OPT 302 through late-stage clinical trials and subsequent commercialization would be key value drivers, potentially unlocking substantial market share in the multi-billion dollar retinal disease therapeutic space.

Based on FMP financials and quantitative analysis

CKDXF Key Highlights

• Opthea Limited maintains a robust gross margin of 100.0%, reflecting its current clinical-stage focus with minimal cost of goods sold.
• The company operates with a market capitalization of $13.68M, indicative of its valuation as a clinical-stage biopharmaceutical entity.
• Opthea's profit margin stands at an exceptionally high 122231.7%, which is characteristic of a company in the development phase that may have recognized one-time gains or non-operating income, rather than consistent product sales.
• The company's stock exhibits a Beta of 1.50, suggesting higher volatility compared to the broader market, typical for a biotechnology company with significant clinical development risks and potential rewards.
• Opthea's lead asset, OPT 302, is a first-in-class VEGF-C/D inhibitor in clinical development for wet AMD and DME, targeting a novel mechanism for retinal disease treatment.

Who Are CKDXF's Competitors?

CKDXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CKDXF's Key Strengths?

• Novel, first-in-class therapeutic candidate (OPT 302) targeting VEGF-C/D, offering a differentiated mechanism of action.
• Strong intellectual property portfolio covering key VEGF pathways (VEGF-C, VEGF-D, and VEGFR-3).
• Addresses significant unmet medical needs in large markets like wet AMD and DME, particularly for suboptimal responders.
• Experienced leadership team with expertise in biopharmaceutical development.

What Are CKDXF's Weaknesses?

• Clinical-stage company with no commercialized products, leading to reliance on external funding and future approvals.
• High dependence on the success of a single lead asset, OPT 302, for its near-term valuation and future prospects.
• Small operational scale with 33 employees, potentially limiting in-house commercialization capabilities.
• Operating on the OTC market, which can present challenges related to liquidity and investor visibility.

What Could Drive CKDXF Stock Higher?

• Announcement of positive top-line data from ongoing late-stage clinical trials for OPT 302 in wet AMD, which could significantly de-risk the asset and increase investor confidence.
• Initiation of new pivotal clinical trials or expansion into additional indications for OPT 302, signaling pipeline progression and broader market potential.
• Formation of a strategic partnership or licensing agreement with a major pharmaceutical company for the global commercialization of OPT 302, providing capital and market access.
• Submission of a New Drug Application (NDA) or Biologics License Application (BLA) to regulatory authorities for OPT 302 in either wet AMD or DME, marking a key step towards market entry.

What Are the Key Risks for CKDXF?

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failure for OPT 302 in either wet AMD or DME, which would severely impact the company's valuation and future prospects.
• Regulatory rejection or significant delays in approval processes for OPT 302, even with positive clinical data, due to unforeseen issues or stringent requirements.
• Intense competition from established anti-VEGF-A therapies and other novel treatments in development for wet AMD and DME, potentially limiting market penetration.
• Insufficient funding to complete ongoing clinical trials and future commercialization efforts, necessitating dilutive equity raises or debt financing.
• The inherent volatility and liquidity challenges associated with trading on the 'OTC Other' market, which can affect investor sentiment and stock price stability.

What Are the Growth Opportunities for CKDXF?

• **Successful Clinical Development and Regulatory Approval for Wet AMD:** The successful completion of late-stage clinical trials for OPT 302 in wet neovascular age-related macular degeneration (wet AMD) and subsequent regulatory approval represents a primary growth driver. The global wet AMD market is projected to reach over $10 billion by the late 2020s. If OPT 302 demonstrates superior efficacy or safety as a combination therapy, it could capture a significant share, particularly among patients who are partial responders to existing VEGF-A inhibitors. The timeline for this opportunity is contingent on ongoing trial results and regulatory review processes, likely extending into the late 2020s.
• **Expansion into Diabetic Macular Edema (DME) Market:** Achieving regulatory approval for OPT 302 in diabetic macular edema (DME) would unlock another substantial market opportunity. The global DME market is also projected to be several billion dollars annually. As a leading cause of vision loss in working-age adults, effective new treatments are highly sought after. Demonstrating OPT 302's efficacy in DME, either as monotherapy or combination therapy, would broaden Opthea's addressable patient population and revenue potential. This development pathway runs concurrently with wet AMD and would follow similar clinical and regulatory timelines.
• **Strategic Partnerships and Global Commercialization:** Given Opthea's clinical-stage status and relatively small employee base of 33, securing strategic partnerships with larger pharmaceutical companies for global commercialization would be a critical growth catalyst. Such partnerships could provide the necessary capital, manufacturing capabilities, and sales infrastructure to effectively launch and distribute OPT 302 worldwide. A successful partnership could significantly accelerate market penetration and maximize the drug's revenue potential, potentially beginning in the late 2020s or early 2030s post-approval.
• **Pipeline Expansion and New Indications:** Beyond OPT 302, leveraging its intellectual property portfolio covering VEGF-C, VEGF-D, and VEGFR-3 to develop additional therapeutic candidates or explore new indications for OPT 302 presents a long-term growth opportunity. This could include other retinal vascular diseases or even non-ophthalmic conditions where these VEGF pathways play a role. A diversified pipeline would reduce reliance on a single asset and provide sustained growth potential for the company into the 2030s and beyond, expanding its market footprint.
• **Addressing Unmet Needs in Suboptimal Responders:** OPT 302's novel mechanism of action, targeting VEGF-C and VEGF-D in addition to VEGF-A, specifically aims to improve outcomes for patients who do not respond adequately to current anti-VEGF-A monotherapies. This segment represents a significant unmet medical need within the wet AMD and DME populations. Successfully demonstrating superior efficacy in these suboptimal responders could establish OPT 302 as a preferred treatment option, carving out a distinct and valuable market niche. This differentiation would be a key competitive advantage, driving adoption upon market entry.

What Opportunities Does CKDXF Have?

• Potential for OPT 302 to achieve superior efficacy as a combination therapy for wet AMD and DME, expanding market share.
• Strategic partnerships or licensing agreements to accelerate global commercialization and mitigate financial risk.
• Expansion of the pipeline by leveraging existing intellectual property for new indications or developing additional candidates.
• Growing global prevalence of age-related macular degeneration and diabetic macular edema, increasing target patient population.

What Threats Does CKDXF Face?

• Risk of clinical trial failure or unfavorable results for OPT 302, leading to delays or abandonment of development.
• Intense competition from established pharmaceutical companies with approved anti-VEGF-A therapies and other novel treatments.
• Regulatory hurdles and potential delays in obtaining marketing approvals from health authorities.
• Challenges in securing adequate funding for ongoing R&D and future commercialization efforts, especially as an OTC-listed company.

What Are CKDXF's Competitive Advantages?

• Proprietary intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3, providing exclusive rights to its therapeutic approach.
• OPT 302's first-in-class mechanism of action as a VEGF-C/D inhibitor offers a differentiated approach compared to existing VEGF-A focused therapies.
• Advanced clinical development stage of OPT 302, which represents a significant barrier to entry for new competitors.
• Specialized scientific expertise in vascular biology and ophthalmology, enabling the development of targeted therapies for complex eye diseases.

What Does CKDXF Do?

Opthea Limited, incorporated in 1984 and headquartered in South Yarra, Australia, is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies primarily for eye diseases. Initially known as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015, signaling a sharpened focus on ophthalmology. The company's core development activities are underpinned by a robust intellectual property portfolio that targets Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3. This scientific foundation is crucial for addressing diseases characterized by abnormal blood and lymphatic vessel growth, as well as vascular leakage, which are central to many debilitating retinal conditions. Opthea's flagship asset is OPT 302, a soluble form of VEGFR-3. This novel therapeutic candidate is currently undergoing clinical development as a potential treatment for two major causes of vision loss: wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is designed to act as a first-in-class inhibitor of VEGF-C and VEGF-D, intended for combination therapy with existing VEGF-A inhibitors. This dual-pathway inhibition strategy aims to provide enhanced efficacy for patients who may not respond optimally to current standard-of-care treatments, which primarily target VEGF-A. By addressing multiple VEGF pathways, Opthea seeks to offer a differentiated approach to managing complex retinal diseases, positioning itself at the forefront of ophthalmological innovation. The company maintains a lean operational structure with 33 employees, focusing its resources on advanced clinical research and development.

What Products and Services Does CKDXF Offer?

• Develops and commercializes therapies primarily for eye diseases, focusing on retinal conditions.
• Utilizes an intellectual property portfolio centered on Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3.
• Their lead asset is OPT 302, a soluble form of VEGFR-3 currently in clinical development.
• OPT 302 is being developed as a novel therapy for wet neovascular age-related macular degeneration (wet AMD).
• OPT 302 is also being developed for diabetic macular edema (DME).
• OPT 302 is designed as a first-in-class VEGF-C/D inhibitor, intended for combination treatment with VEGF-A inhibitors.
• Aims to treat diseases associated with abnormal blood and lymphatic vessel growth, as well as vascular leakage in the eye.

How Does CKDXF Make Money?

• Primarily focused on research and development (R&D) of novel biopharmaceutical compounds for eye diseases.
• Future revenue generation is contingent upon successful clinical trials, regulatory approvals, and subsequent commercialization of its lead asset, OPT 302.
• Potential for licensing agreements or strategic partnerships with larger pharmaceutical companies for global distribution and sales.
• Monetization through direct sales of approved drugs in select markets or royalty payments from partners.
• Relies on intellectual property protection for its VEGF-C, VEGF-D, and VEGFR-3 related therapies.

What Industry Does CKDXF Operate In?

Opthea Limited operates within the highly specialized and competitive biotechnology industry, specifically focusing on ophthalmology. The market for treating retinal diseases, particularly wet age-related macular degeneration (AMD) and diabetic macular edema (DME), is substantial and growing, driven by an aging global population and increasing prevalence of diabetes. Current treatments largely revolve around anti-VEGF-A therapies, which have revolutionized care but still leave a segment of patients with suboptimal responses. Opthea's lead asset, OPT 302, aims to differentiate itself by targeting VEGF-C and VEGF-D, offering a potential first-in-class combination therapy to improve outcomes. This positions Opthea within the innovative segment of the industry, seeking to expand beyond existing treatment paradigms. The competitive landscape includes major pharmaceutical companies with established anti-VEGF-A drugs, as well as other biotechs developing novel mechanisms or next-generation therapies for these conditions.

Who Are CKDXF's Key Customers?

• Future customers will primarily be ophthalmologists and retina specialists who prescribe treatments for retinal diseases.
• Ultimately, patients suffering from wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
• Healthcare systems, hospitals, and clinics that procure and administer specialized eye disease therapies.
• Potentially, pharmaceutical companies seeking to license or partner on novel ophthalmology treatments.

Company Profile

Opthea Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South Yarra, AU. The company is led by CEO Jeremy Max Levin Ba Zoology Dphil Mb Bchir. CKDXF has traded publicly since 2011.

ROE 44%Key Financial Metrics

Return on equity for Opthea Limited stands at 44.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -21.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.22 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -16.0%, the inverse of the P/E and a quick read on earnings relative to price.

CKDXF Valuation & Market Position

With a $13.68M market cap, Opthea Limited sits in the micro-cap segment of the market. Relative to its peer group, CKDXF's quantitative score of 53/100 is below the peer average of 76/100.

Quarterly Financial Performance: Opthea Limited

Revenue for Opthea Limited came in at $3K during Q2 2025, a 89.4% contraction versus the preceding quarter. The company recorded a net loss of $32.0M, with diluted EPS of $-0.03. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely.

F-Score 1/9Financial Health

Opthea Limited's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

FY2026 estForward Outlook

Wall Street analysts project Opthea Limited revenue of about $200K for fiscal 2026, with EPS near $-0.00.

CKDXF Financials

CKDXF Latest News

No recent news available for CKDXF.

CKDXF Analyst Consensus

CKDXF MoonshotScore

Common Questions About CKDXF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources